soul trial oral semaglutide cardiovascular outcomes results 2024 nejm Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial soul trial oral semaglutide cardiovascular

Beyond Lilly and Novo Nordisk, challengers such as Amgen (MariTide), Viking Therapeutics (VK2735, including an oral form), Boehringer Ingelheim/Zealand Pharma (survodutide) and Innovent (mazdutide) are each pursuing multi-indication development spanning obesity, type 2 diabetes, cardiovascular risk, MASH and sleep apneanot just building a single blockbuster, but positioning for the same portfolio logic as the incumbents

Rhamnosus CNCM I-3690 survival, adaptation, and small bowel microbiome impact in human

Lifestyle Test Measure cholesterol, liver, kidney and blood sugar markers a simple baseline for understanding your core health

10.1007/s40262-021-01025-x 12 PechenovS.RevellJ.WillS.NaylorJ.TyagiP.PatelC.et al (2021)